Best Weight Loss Supplements in 2026 — Ranked & Reviewed
We independently evaluated and scored the top weight loss supplements of 2026 based on value, effectiveness, user experience, and more.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Buoy
Best for: GLP-1-companion electrolyte supplement
Buoy (justaddbuoy.com) is a liquid electrolyte drop with 87+ trace minerals, vitamins, and antioxidants from an ocean-electrolyte and whole-food base. Buoy markets itself as a general hydration and electrolyte product, NOT as a weight-loss or GLP-1-specific product — we list it here because electrolyte loss is a documented side effect of rapid GLP-1-mediated weight loss, but readers should know the GLP-1 framing is editorial, not the brand's own primary positioning.
Score Breakdown
Pros
- ✓Liquid format mixes into any beverage — easier compliance than electrolyte powders
- ✓Sugar-free / no artificial sweeteners (per brand positioning)
- ✓Useful adjunct for GLP-1 patients who experience electrolyte loss from reduced appetite and rapid weight loss
Cons
- ✗Stub entry — exact pricing, ingredient panel per serving, and clinical positioning need a YMYL verification pass
- ✗Confidence is LOW until that pass is done
- ✗Not a substitute for prescription electrolyte management in clinically significant cases
Gruns Greens
Best for: daily-multivitamin gummy as a GLP-1 nutrition adjunct
Gruns is a daily greens gummy positioned as a more palatable alternative to powdered greens and traditional multivitamins. Marketed as a nutrition-density tool that pairs with weight-loss diets and GLP-1 therapy to maintain micronutrient intake when overall food intake drops.
Score Breakdown
Pros
- ✓Gummy format is dramatically more compliance-friendly than powdered greens or capsule multivitamins
- ✓Useful for GLP-1 patients who experience reduced appetite and need a low-volume way to maintain micronutrient intake
- ✓Brand-recognition lever — Gruns has run high-visibility marketing campaigns through 2024-2025
Cons
- ✗Stub entry — exact ingredient panel, third-party lab testing, FDA adverse actions, and pricing tiers need a YMYL verification pass
- ✗Confidence is LOW until that pass is done
- ✗Not a substitute for clinical nutrition management — greens supplements have weak evidence relative to whole-food vegetable intake
IM8 Health
Best for: all-in-one daily greens-and-vitamin blend with independent third-party (NSF) quality testing
IM8 Health is a daily health drink and supplement system co-founded by David Beckham and Prenetics CEO Danny Yeung, positioning itself as an all-in-one greens, prebiotic, probiotic, vitamin, mineral, and adaptogen blend. Marketed for energy, gut health, longevity, and metabolic support. Distributed in the US by Prenetics Global Limited.
Score Breakdown
Pros
- ✓All-in-one daily blend reduces stack complexity vs. taking 5-10 separate supplements
- ✓NSF Certified for Sport — independent third-party testing for banned-substance contamination and label accuracy
- ✓Scientific advisory board includes Dr. James L. Green (former NASA Chief Scientist) and Dr. Dawn Mussallem (Mayo Clinic)
Cons
- ✗Newer brand (US launched December 2024) — long-term outcome data does not exist yet
- ✗Not a weight-loss product — marketed as general wellness/longevity, not a metabolic-support therapy
- ✗Not a substitute for whole-food nutrition or clinical supplementation
- ✗Exact ingredient doses per serving and full ingredient panel still need to be pulled off-site before featuring
fatty15
Best for: single-ingredient C15:0 longevity supplement
fatty15 is a daily C15:0 (pentadecanoic acid) supplement marketed for cellular longevity, metabolic health, and inflammation reduction. C15:0 is an odd-chain saturated fatty acid that the company's published research positions as the first essential fatty acid to be discovered in 90+ years, with claimed effects on cell membrane stability and mitochondrial function.
Score Breakdown
Pros
- ✓Single-ingredient supplement with a clear mechanism (C15:0 cell-membrane stability) and a published research portfolio behind it
- ✓Strong brand-recognition lever — fatty15 has run high-profile longevity-content marketing through 2024-2025
- ✓Pure C15:0 is hard to sourcefrom diet alone (mainly found in dairy fat) so supplementation has a defensible nutritional rationale for some patients
Cons
- ✗Stub entry — exact pricing, ingredient panel, third-party lab testing, FDA / FTC adverse actions, and the longevity / metabolic claims all need a YMYL verification pass
- ✗Confidence is LOW until that pass is done
- ✗C15:0 essential-fatty-acid status is the company's own positioning; independent peer-reviewed consensus on whether it should be classified as essential is still developing
- ✗Not a weight-loss product per se — listed here because longevity / cellular health overlaps with our metabolic-health editorial scope, not because it directly causes weight loss
Enhanced
Best for: Not a GLP-1 provider. Listed for completeness only; users seeking weight-loss medication should consider the GLP-1 Provider directory instead.
Enhanced (enhanced.com / shop.enhanced.com) is the consumer brand associated with the Enhanced Games athletic competition. It is NOT a GLP-1 weight-loss telehealth provider. The shop sells two retail dietary supplements — LONGER+ (longevity) and STRONGER+ (performance), each $200 regular / $125 sale — plus branded apparel. The corporate site references 'LIVE ENHANCED' and 'LIVE ENHANCED+' as 'science-backed protocols' and 'personalized wellness products and pathways,' but the public store does not list any GLP-1 (semaglutide/tirzepatide), testosterone/TRT, or compounded peptide products, nor a LegitScript seal, nor any state-by-state telehealth coverage. Standard FDA dietary-supplement disclaimer is published verbatim: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.' Corporate copyright lists 'Enhanced Ltd.' Listed here as a Supplement-category reference, NOT as a weight-loss telehealth provider — readers researching GLP-1s should not interpret this listing as a comparable option.
Score Breakdown
Pros
- ✓Public pricing on retail supplements
- ✓Transparent FDA dietary-supplement disclaimer
Cons
- ✗Not a GLP-1 weight-loss telehealth provider — outside WLR core directory scope
- ✗No prescription medications, peptides, or compounded drugs offered to consumers
- ✗Affiliated with the controversial Enhanced Games competition (performance-enhancement context)
- ✗No LegitScript seal; no licensed-provider network disclosed
- ✗Active ingredients in LONGER+ / STRONGER+ not disclosed on visible pages
Related Rankings
Frequently Asked Questions
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.